Similarly, A-1331852 sensitized the BT-474 and MDA-MB-453 cells to dinaciclib while venetoclax either did not (BT-474) or had a minimal effect (MDA-MB-453); strikingly, however, A-1210477 had no sensitizing effect on dinaciclib, consistent with MCL-1 as the key dinaciclib target in HER2-amplified breast cancer (Suplementary Fig. 4B, D). The gene discussed is ERBB2; the disease is breast carcinoma.